于波中國醫(yī)大一院-閱讀頁
2025-08-02 06:36本頁面
【正文】 of ReninAngiotensinAldosterone System 2022。 procedures， 142 pts on RASI ?Median followup ( ) yrs Takigawa M et al. Journal of ReninAngiotensinAldosterone System 2022。 為房顫消融術(shù)后短期復(fù)發(fā)可能是由于炎癥反應(yīng)這一說法提供證據(jù) ?激素各種限制，妨礙其中期和長期使用 ?高血壓、冠心病或糖尿病 ?減緩消融組織愈合，可能增加消融相關(guān)并發(fā)癥如心房食管瘺或亞急性心包積液 85% 71% Spyridon Deftereos , J Am Coll Cardiol. 2022, 60(18): 1790–1796 Colchicine for Prevention of ERAF After PVI ?術(shù)后第 3天開始秋水仙堿 mg 日二次，然后 mg日二治療 1個月 ≥70 kg, 70 kg減半或最大耐受量 ? 一級終點： POAF發(fā)生率 秋水仙堿具有潛在抗炎作用 170陣發(fā)性房顫行 PVI后隨機行秋水仙堿或安慰劑 AF Recurrence According to OnTreatment IL6 Levels during 3month study Predictors of Recurrence KaplanMeier curves of the cumulative hazard of AF recurrence according to age, hypertension, LA, and IL6 Spyridon Deftereos , J Am Coll Cardiol. 2022, 60(18): 1790–1796 AF Recurrence in the 2 Group ?秋水仙堿治療減少POAF (% /%, P=） ? 住院時間更短 (177。 days。 vs 177。 P=) ?副作用相似 ?結(jié)論：秋水仙堿安全有效地減少 POAF，減少住院日 Spyridon Deftereos , J Am Coll Cardiol. 2022, 60(18): 1790–1796 3個月后秋水仙堿組早期房顫復(fù)發(fā)率明顯低于安慰劑組 他汀類藥物與房顫復(fù)發(fā) ? Suleiman，前瞻性，隨機，安慰劑對照研究，分析有癥狀房顫患者經(jīng) PVI后 AF復(fù)發(fā)而沒有使用至少一種 AAD患者應(yīng)用他汀類藥物效果 ? 結(jié)論：消融前阿托伐他汀 80mg/天并不降低前 3個月房顫復(fù)發(fā)風(fēng)險，不應(yīng)常規(guī)給予預(yù)防圍手術(shù)期心律失常 雷諾嗪與房顫復(fù)發(fā) Heart Rhythm, Vol 9, No 4, April 2022 2022 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Remendations for Patient Selection, Procedural Techniques, Patient Management and Followup, Definitions, Endpoints, and Research Trial Design The European AF Ablation Pilot registry Study: The EURObservational Research Programme (EORP) ? a prospective registry to describe the clinical epidemiology of AF ablation, and the diagnostic/therapeutic processes applied in Europe ? Arrhythmia documentation was done by an ECG in 76%, Holter in 52%, transtelephonic monitoring in 8%, and/or implanted systems in % Eur Heart J June 21, 2022 35 (24) First published online: January 31, 2022 72 centres in 10 countries to enrol 20pts doing a 1st PVI Oct, 2022 May, 2022 1391 pts PVI(%),1300 pts (%) pleted followup 367 177。 % in persistent AF。11(7):837842. 房顫導(dǎo)管消融術(shù)后抗心律失常藥物的應(yīng)用：時機與建議
語文相關(guān)推薦
鄂ICP備17016276號-1